People: Vanda Pharmaceuticals Inc (VNDA.O)

VNDA.O on Consolidated Issue listed on NASDAQ Global Market

12.58USD
21 Nov 2014
Price Change (% chg)

$0.59 (+4.92%)
Prev Close
$11.99
Open
$12.22
Day's High
$12.65
Day's Low
$12.05
Volume
697,427
Avg. Vol
602,051
52-wk High
$19.25
52-wk Low
$8.34

Search Stocks

Kelly, James 

Brief Biography

Mr. James Patrick Kelly is Chief Financial Officer, Senior Vice President, Treasurer, Secretary of Vanda Pharmaceuticals Inc., since December 13, 2010. Prior to joining Vanda, Mr. Kelly was Vice President and Controller at MedImmune, a biotechnology subsidiary of the AstraZeneca Group. Mr. Kelly joined MedImmune in 2006 as Director of Sales and Marketing Finance. From 2000 through 2005, Mr. Kelly was at Biogen Idec serving in research and development finance roles of increasing responsibility, most recently as the Director of Planning and Operations. From 1997-2000, Mr. Kelly was a member of the corporate finance team at Aetna Inc. which was responsible for mergers and acquisitions and treasury management. Mr. Kelly began his life sciences career in 1991 with Janssen Pharmaceutica, a division of Johnson & Johnson. Mr. Kelly is a CFA charterholder and a member of the Association of Bioscience Financial Officers (“ABFO”). He received his Master of Business Administration degree from Cornell University and his Bachelor of Sciences degree in Business Administration from the University of Vermont.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
472,500 -- 441,078 1,145,380

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Howard Pien

--

Mihael Polymeropoulos

2,520,230

James Kelly

1,145,380

Paolo Baroldi

1,111,410

Michael Cola

--

Richard Dugan

--
As Of 30 Dec 2013
Search Stocks